PRISM MediaWire

Sports Gear and Apparel

DRYWORLD Brands (IBGR) Strategically Positions Itself for Game-Changing Impact in 2024 Following Dynamic Moves in 2023

New York, March 05, 2024 - PRISM MediaWire - Today, DRYWORLD Brands, Inc. ($IBGR), a leading global sports brand renowned for premium performance, delivered its annual corporate update to the investment community. The update showcased remarkable achievements, including a...

5 March 2024

Topline Data Anticipated for Suicidal Bipolar Depression Treatment Trial by NRx

New York, March 05, 2024 - PRISM MediaWire - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) achieves 'Last Patient, Last Visit' milestone in Phase 2b/3 Trial of NRX-101 for suicidal treatment-resistant bipolar depression. The company confirms completion of the 74th and final e...

5 March 2024

Quoin Pharmaceuticals Expands Rare Disease Clinical Trials to Encompass Teen Patients

New York, March 04, 2024 - PRISM MediaWire - Clinical-stage biotechnology firm Quoin Pharmaceuticals (Nasdaq: QNRX) has obtained FDA clearance to enroll subjects aged 14 years and above into its two ongoing clinical trials for QRX003. These trials are dedicated to assess...

4 March 2024

Artificial Intelligence:

Advancements in Artificial Intelligence Enhance Travel Experience in 2024: TSA Precheck and Airlines Introduce "Touchless ID" System; BBAI Stock Surges Approximately 30% Following Announcement of "Vision AI" Acquisition

New York, March 04, 2024 - PRISM MediaWire - United Airlines (UA) is set to introduce "Touchless ID" technology, replacing traditional boarding passes and IDs for passengers traveling through Chicago O'Hare and Los Angeles International airports. The program is slated fo...

4 March 2024

NeuroBo Pharmaceuticals to Commence Clinical Trial Addressing Obesity

New York, March 04, 2024 - PRISM MediaWire - NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has obtained Institutional Review Board (IRB) approval to advance its Phase 1 clinical trial of DA-1726, targeting obesity treatment. Anticipated commencement of patient randomizati...

4 March 2024

Lexaria to Progress CBD Hypertension Candidate Following IND Approval

New York, March 01, 2024 - PRISM MediaWire - Lexaria Bioscience (Nasdaq: LEXX) has made significant strides in advancing its CBD-based candidate for hypertension, marked by the recent clearance of its investigational new drug (IND) application by the FDA. With this regul...

1 March 2024

Electric Vehicles

Exploring AI Integration in Electric Vehicles: Indie Semiconductor (INDI) Forges Ahead, Achieves Electrifying Earnings, Establishes Strategic AI Partnership

New York, N.Y., February 29, 2024 - PRISM MediaWire - Indie Semiconductor, Inc. (INDI), renowned for its automotive software solutions and semiconductor expertise, has significantly propelled the advancement of vehicle electrification. In its recent report on Q4 earnings...

1 March 2024

Medical Devices

Establishment Labs Holdings (ESTA) Nearly Doubles Share Price Following Debut on PRISM Women’s Health Index Two Months Ago

New York, N.Y., February 29, 2024 - PRISM MediaWire - Establishment Labs Holdings Inc. (ESTA) surged by 24% today, continuing its upward trajectory that began at the onset of the year. Included in the PRISM Women’s Health Index since its inauguration on January 4th, the ...

29 February 2024

Artificial Intelligence:

"LivePerson, Inc. Shares Plummet 42% Following Q4 Loss and Missed Estimates

New York, N.Y., February 29, 2024 - PRISM MediaWire - LivePerson, Inc. (NASDAQ: LPSN) is currently experiencing significant challenges, evident in its impact on the PRISM NextGen Tech & AI Index where it stands as the largest detractor, causing a notable decline of a...

29 February 2024

Enveric Biosciences Makes Strides in Mental Health Treatment, Witnesses 127% Surge in Shares through Out-Licensing of Compound Classes

New York, N.Y., February 29, 2024 - PRISM MediaWire - Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm specializing in the development of neuroplastogenic small-molecule therapeutics for mental health disorders, has announced the initiation of negotiations via th...

29 February 2024